Document Detail

Augmented therapy of extensive Hodgkin's disease: radiation to known disease or prolongation of induction chemotherapy did not improve survival--results of a Cancer and Leukemia Group B study.
MedLine Citation:
PMID:  9635714     Owner:  NLM     Status:  MEDLINE    
PURPOSE: This prospective randomized trial in extensive untreated Hodgkin's disease was undertaken to assess the potential benefit of augmented therapy (12 months chemotherapy or radiation to known disease) compared to standard 6 months chemotherapy. PATIENT AND METHODS: A total of 258 patients, mostly Stage IV, were randomized to four treatment regimens consisting of six cycles of CCNU, vinblastine, procarbazine, and prednisone (CVPP); 12 cycles of CVPP; six cycles of CVPP followed by 25 Gy radiotherapy; or three cycles CVPP, 25 Gy radiotherapy, and three cycles CVPP. RESULTS: Complete remissions were achieved in 65% of all patients. A 58% overall 5-year survival rate was obtained. Relapses in irradiated areas of known disease occurred in only 6% of responding patients. There was, however, no statistical difference in response frequency, disease-free survival, or overall survival among the four regimens. Elderly patients responded less frequently. CONCLUSION: While radiotherapy provided control of local (known) disease, no impact on overall survival was apparent. Likewise, doubling the duration of chemotherapy did not improve response or survival. Augmentation of therapy with either radiotherapy or more chemotherapy in this study was of no benefit compared to the standard 6 months of treatment.
M Coleman; S Rafla; K J Propert; A Glicksman; B Peterson; N Nissen; K Brunner; J F Holland; J R Anderson; A Gottlieb; T Kaufman
Related Documents :
1493474 - Massive mediastinal involvement in stage i-ii hodgkin's disease: response to combined m...
387804 - Hodgkin's disease in childhood.
17762404 - Radioimmunotherapy of refractory or relapsed hodgkin's lymphoma with 90y-labelled antif...
15981804 - Hodgkin lymphoma involving waldeyer ring: a clinicopathologic study of 22 cases.
23860204 - Adding epoetin alfa to intense dose-dense adjuvant chemotherapy for breast cancer: rand...
10228794 - Sialyl tn antigen expression is associated with the prognosis of patients with advanced...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  41     ISSN:  0360-3016     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  1998 Jun 
Date Detail:
Created Date:  1998-06-30     Completed Date:  1998-06-30     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  639-45     Citation Subset:  IM    
New York Hospital-Cornell Medical Center, NY 10021, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Combined Modality Therapy
Disease-Free Survival
Hodgkin Disease / drug therapy*,  radiotherapy*
Lomustine / administration & dosage
Middle Aged
Prednisone / administration & dosage
Procarbazine / administration & dosage
Prospective Studies
Vinblastine / administration & dosage
Grant Support
Reg. No./Substance:
0/CVPP protocol; 13010-47-4/Lomustine; 53-03-2/Prednisone; 671-16-9/Procarbazine; 865-21-4/Vinblastine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Disposition and tissue distribution of boron after infusion of borocaptate sodium in patients with m...
Next Document:  Outcomes of high-dose unilateral kidney irradiation in patients with gastric lymphoma.